No products in the cart.
Pre-made Cevostamab benchmark antibody ( Bispecific mAb, anti-FCRL5;CD3 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-103
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Cevostamab biosimilar, Bispecific mAb: Anti-FCRL5;CD3 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
A proprietary recombinant bispecific T-cell engager (BiTE) antibody composed of two single-chain variable fragments (scFv), one directed against the tumor-associated antigen (TAA) Fc receptor-like protein 5 (FCRH5; CD307; FCRL5; IRTA2; BXMAS1) and one that is directed against the CD3 antigen found on T lymphocytes, with potential immunostimulating and antineoplastic activities.
| Products Name (INN Index) | Pre-Made Cevostamab biosimilar, Bispecific mAb: Anti-FCRL5;CD3 therapeutic antibody |
|---|---|
| INN Name | Cevostamab |
| Target | FCRL5,CD3 |
| Format | Bispecific mAb |
| Derivation | Bispecific antibody |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa,Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None;None |
| 99% SI Structure | None;None |
| 95-98% SI Structure | None;None |
| Year Proposed | 2019 |
| Year Recommended | 2020 |
| Companies | Genentech |
| Conditions Approved | NA |
| Conditions Active | Multiple myeloma |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | FCRL5,CD3 |
| Package |
Previous slide
Next slide
